Rituximab

Five-year data from the MURANO study showed a continued PFS benefit with venetoclax-rituximab vs. bendamustine-rituximab among patients with relapsed or refractory chronic lymphocytic leukemia.

While we know women are threefold more likely than men to receive an MS diagnosis and they are usually diagnosed during their childbearing years, data on the impact of pregnancy on MS outcomes remain less clear.

IgG4-related disease treatment is expected evolve greatly over the next 3 to 5 years, with a trio of promising drugs — inebilizumab, rilzabrutinib and elotuzumab — on the horizon, according to a speaker at the 2020 Congress of Clinical Rheumatology-West.

Low doses of rituximab provided patients with MS an effective treatment option and an improved safety profile compared with higher doses of the agent, according to findings presented at MSVirtual2020.

Acalabrutinib appeared effective and safe compared with standard regimens for relapsed or refractory chronic lymphocytic leukemia, according to long-term study results presented at Society of Hematologic Oncology Annual Meeting.

Rituximab, used alongside glucocorticoids, is highly efficacious in re-inducing remission among relapsed patients with ANCA-associated vasculitis, according data published in Annals of the Rheumatic Diseases.

The long-term safety of rituximab was consistent with a shorter duration of treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis, according to data published in Arthritis Care & Research.

Rituximab contributed to reaching complete remission and reduced steroid use in patients with bullous pemphigoid, but did not increase overall survival, according to a poster presented at the American Academy of Dermatology virtual meeting.

A biannual regimen of rituximab infusions over the course of 18 months was associated with a lower incidence of relapse in ANCA-associated vasculitis, compared with standard maintenance therapy, according to data published in the Annals of Internal Medicine.

The addition of rituximab to standard lymphomes malins B chemotherapy improved EFS and OS among a subset of pediatric patients with non-Hodgkin lymphoma, according to study results published in The New England Journal of Medicine.